3 ms·
When comparing to the baseline, we need to divde the per year stats to some shorter time period, because these AstraZeneca related cases happen pretty quickly a
by Strom 6y ago
When comparing to the baseline, we need to divde the per year stats to some shorter time period, because these AstraZeneca related cases happen pretty quickly after the jab, which means that the observation period isn't a full year.
It's also worth looking at the age distribution. The cases that are thought to be linked with AstraZeneca are with younger people. I wonder how that compares to the baseline thrombosis age distribution.
- vmception 6y agoIn full 3-stage clinical trials, would this cause passage with a disclaimer about side effects, or would this cause failure? I don't have enough information about this sector to tell
- AstralStorm 6y agoPhase 3 trials are typically not big enough to find this level of risk. It took millions of jabs to find a slightly elevated risk, and this I think has to be compared to some other commonly applied vaccine, not placebo. If the risk is "very rare", like less than 1 in 10000, then it warrants a label and maybe precautionary dose of aspirin.